BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bergmann C, Distler JHW, Treutlein C, Tascilar K, Müller A, Atzinger A, Matei A, Knitza J, Györfi A, Lück A, Dees C, Soare A, Ramming A, Schönau V, Distler O, Prante O, Ritt P, Götz TI, Köhner M, Cordes M, Bäuerle T, Kuwert T, Schett G, Schmidkonz C. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. The Lancet Rheumatology 2021;3:e185-94. [DOI: 10.1016/s2665-9913(20)30421-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Hotta M, Rieger AC, Jafarvand MG, Menon N, Farolfi A, Benz MR, Calais J. Non-oncologic incidental uptake on FAPI PET/CT imaging. Br J Radiol 2023;96:20220463. [PMID: 35776566 DOI: 10.1259/bjr.20220463] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
2 Cselényi Z, Jucaite A, Ewing P, Stenkrona P, Kristensson C, Johnström P, Schou M, Bolin M, Halldin C, Larsson B, Grime K, Eriksson UG, Farde L. Proof of lung muscarinic receptor occupancy by tiotropium: Translational Positron Emission Tomography studies in non-human primates and humans. Front Nucl Med 2023;2. [DOI: 10.3389/fnume.2022.1080005] [Reference Citation Analysis]
3 Montesi SB, Horowitz JC. Fibroblast Activating Protein: Skimming the Surface of Molecular Imaging to Assess Fibrotic Disease Activity. Am J Respir Crit Care Med 2023;207:122-4. [PMID: 36075072 DOI: 10.1164/rccm.202208-1638ED] [Reference Citation Analysis]
4 Barton AK, Tzolos E, Bing R, Singh T, Weber W, Schwaiger M, Varasteh Z, Slart RHJA, Newby DE, Dweck MR. Emerging molecular imaging targets and tools for myocardial fibrosis detection. Eur Heart J Cardiovasc Imaging 2022:jeac242. [PMID: 36575058 DOI: 10.1093/ehjci/jeac242] [Reference Citation Analysis]
5 Treutlein C, Distler JHW, Tascilar K, Fakhouri SC, Györfi A, Atzinger A, Matei A, Dees C, Büttner-herold M, Kuwert T, Prante O, Bäuerle T, Uder M, Schett G, Schmidkonz C, Bergmann C. Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT. Eur J Nucl Med Mol Imaging 2022. [DOI: 10.1007/s00259-022-06081-4] [Reference Citation Analysis]
6 Broens B, Duitman JW, Zwezerijnen GJC, Nossent EJ, van der Laken CJ, Voskuyl AE. Novel tracers for molecular imaging of interstitial lung disease: A state of the art review. Autoimmun Rev 2022;21:103202. [PMID: 36150433 DOI: 10.1016/j.autrev.2022.103202] [Reference Citation Analysis]
7 Schmidkonz C, Kuwert T, Atzinger A, Cordes M, Schett G, Ramming A, Götz T. Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging. J Nucl Med 2022;63:1786-92. [PMID: 36109182 DOI: 10.2967/jnumed.122.264205] [Reference Citation Analysis]
8 van den Hoven AF, Keijsers RGM, Lam MGEH, Glaudemans AWJM, Verburg FA, Vogel WV, Lavalaye J. Current research topics in FAPI theranostics: a bibliometric analysis. Eur J Nucl Med Mol Imaging 2022. [DOI: 10.1007/s00259-022-06052-9] [Reference Citation Analysis]
9 Dilsizian V, Chandrashekhar Y. Molecular Imaging: New Promises. JACC Cardiovasc Imaging 2022;15:2019-21. [PMID: 36357149 DOI: 10.1016/j.jcmg.2022.10.001] [Reference Citation Analysis]
10 Sarbu A, Maurer B. Die interstitielle Lungenerkrankung bei systemischer Sklerose. Arthritis und Rheuma 2022;42:330-336. [DOI: 10.1055/a-1893-4920] [Reference Citation Analysis]
11 Vorster M. Gallium-68 Labelled Radiopharmaceuticals for Imaging Inflammatory Disorders. Seminars in Nuclear Medicine 2022. [DOI: 10.1053/j.semnuclmed.2022.08.005] [Reference Citation Analysis]
12 Guarneri A, Perrone E, Bosello SL, D’agostino MA, Leccisotti L. The role of PET/CT in connective tissue disorders: systemic sclerosis, Sjögren's syndrome and systemic lupus erythematosus. Q J Nucl Med Mol Imaging 2022;66. [DOI: 10.23736/s1824-4785.22.03463-x] [Reference Citation Analysis]
13 Fang Q, Liu S, Cui J, Zhao R, Han Q, Hou P, Li Y, Lv J, Zhang X, Luo Q, Wang X. Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy. Front Bioeng Biotechnol 2022;10:920766. [DOI: 10.3389/fbioe.2022.920766] [Reference Citation Analysis]
14 Hoffmann-Vold AM, Distler O, Crestani B, Antoniou KM. Recent advances in the management of systemic sclerosis-associated interstitial lung disease. Curr Opin Pulm Med 2022. [PMID: 35855572 DOI: 10.1097/MCP.0000000000000901] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Broens B, van der Laken CJ, Zwezerijnen GJ, Nossent EJ, Meijboom LJ, Spierings J, de Vries-bouwstra JK, van Laar JM, Voskuyl AE. Positron Emission Tomography to Improve Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation. Front Immunol 2022;13:923869. [DOI: 10.3389/fimmu.2022.923869] [Reference Citation Analysis]
16 Raju S, Shukla J, Kumar R. Fibroblast Activation Protein Inhibitor Theranostics. PET Clin 2022;17:453-64. [PMID: 35717101 DOI: 10.1016/j.cpet.2022.03.005] [Reference Citation Analysis]
17 Carvajal Alegria G, Croft AP. Fibroblasts, a target for imaging and therapeutics in rheumatoid arthritis. Rheumatology (Oxford) 2021:keab845. [PMID: 34791115 DOI: 10.1093/rheumatology/keab845] [Reference Citation Analysis]
18 Schmidkonz C. Perspective on Fibroblast Activation Protein-Specific PET/CT in Fibrotic Interstitial Lung Diseases: Imaging Fibrosis-A New Paradigm for Molecular Imaging? J Nucl Med 2022;63:125-6. [PMID: 34649945 DOI: 10.2967/jnumed.121.262944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Distler JH, Bergmann C, Kuwert T, Schmidkonz C. Quantification of 68Ga-FAPI-04 in systemic sclerosis-associated interstitial lung disease – Authors' reply. The Lancet Rheumatology 2021;3:e475-e477. [DOI: 10.1016/s2665-9913(21)00147-8] [Reference Citation Analysis]
20 Broens B, Zwezerijnen BGJC, van der Laken CJ, Voskuyl AE. Quantification of 68Ga-FAPI-04 in systemic sclerosis-associated interstitial lung disease. The Lancet Rheumatology 2021;3:e475. [DOI: 10.1016/s2665-9913(21)00143-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Volkmann ER. Molecular imaging for systemic sclerosis-interstitial lung disease. The Lancet Rheumatology 2021;3:e163-e164. [DOI: 10.1016/s2665-9913(21)00004-7] [Reference Citation Analysis]